News Industry News U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance® (empagliflozin) January 24, 2016
News Industry News Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events August 20, 2015
News Industry News Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions June 05, 2015